These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 19453401)

  • 21. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.
    Galli G; Hancock K; Hoschler K; DeVos J; Praus M; Bardelli M; Malzone C; Castellino F; Gentile C; McNally T; Del Giudice G; Banzhoff A; Brauer V; Montomoli E; Zambon M; Katz J; Nicholson K; Stephenson I
    Proc Natl Acad Sci U S A; 2009 May; 106(19):7962-7. PubMed ID: 19416838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets.
    Forrest HL; Khalenkov AM; Govorkova EA; Kim JK; Del Giudice G; Webster RG
    Vaccine; 2009 Jun; 27(31):4187-95. PubMed ID: 19406182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.
    Camilloni B; Basileo M; Valente S; Nunzi E; Iorio AM
    Hum Vaccin Immunother; 2015; 11(3):553-63. PubMed ID: 25714138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults.
    Banzhoff A; Gasparini R; Laghi-Pasini F; Staniscia T; Durando P; Montomoli E; Capecchi PL; di Giovanni P; Sticchi L; Gentile C; Hilbert A; Brauer V; Tilman S; Podda A
    PLoS One; 2009; 4(2):e4384. PubMed ID: 19197383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
    Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.
    Solares AR; Aragon CG; Pivaral RU; Prado-Cohrs D; Sales-Carmona V; Pellegrini M; Groth N
    J Infect Dev Ctries; 2014 Sep; 8(9):1160-8. PubMed ID: 25212080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.
    Frey SE; Reyes MR; Reynales H; Bermal NN; Nicolay U; Narasimhan V; Forleo-Neto E; Arora AK
    Vaccine; 2014 Sep; 32(39):5027-34. PubMed ID: 25045825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.
    Ansaldi F; Bacilieri S; Durando P; Sticchi L; Valle L; Montomoli E; Icardi G; Gasparini R; Crovari P
    Vaccine; 2008 Mar; 26(12):1525-9. PubMed ID: 18294741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.
    Puig Barberà J; González Vidal D
    Expert Rev Vaccines; 2007 Oct; 6(5):659-65. PubMed ID: 17931147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.
    Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli G; Groth N; Del Giudice G
    Hum Vaccin Immunother; 2012 Feb; 8(2):216-27. PubMed ID: 22426371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
    Nolan T; Bravo L; Ceballos A; Mitha E; Gray G; Quiambao B; Patel SS; Bizjajeva S; Bock H; Nazaire-Bermal N; Forleo-Neto E; Cioppa GD; Narasimhan V
    Vaccine; 2014 Oct; 32(46):6146-56. PubMed ID: 25223266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.
    Feldstein LR; Matrajt L; Elizabeth Halloran M; Keitel WA; Longini IM;
    Vaccine; 2016 Jul; 34(33):3796-802. PubMed ID: 27268778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects.
    Vesikari T; Forstén A; Borkowski A; Gaitatzis N; Banzhoff A; Clemens R
    Hum Vaccin Immunother; 2012 Jul; 8(7):921-8. PubMed ID: 22777094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
    Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
    Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages.
    Camilloni B; Neri M; Lepri E; Iorio AM
    Vaccine; 2009 Jun; 27(31):4099-103. PubMed ID: 19410623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.
    Orsi A; Ansaldi F; de Florentiis D; Ceravolo A; Parodi V; Canepa P; Coppelli M; Icardi G; Durando P
    Hum Vaccin Immunother; 2013 Mar; 9(3):582-90. PubMed ID: 23295230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.